viewDel Frisco's Restaurant Group Inc

Del Frisco operator's shares plunge after missing on 1Q profit and announcing acquisition of Barteca

Investors think the US$325mln merger may be hard to swallow

Del Frisco's steak house
Del Frisco's is looking to woo a new breed of customers by acquiring Barteca, owner of Barcelona, an upmarket tapas restaurant

Shares of Del Frisco’s Restaurant Group (NASDAQ:DFRG), operator of Del Frisco’s Double Eagle Steakhouse, Del Frisco’s Grille and Sullivan’s Steakhouse, plunged in afternoon trade after missing on its first-quarter profit and revealing its intention to acquire Barteca Restaurant Group for US$325mln in cash.

In the first piece of news, the restaurant chain posted net income of $400,000, or US$0.02 per share, compared with US$3.3mln, or US$0.14, in the year-ago quarter.

With the exclusion of items on an adjusted basis, its earnings amounted to US$0.10, which fell way short of Wall Street’s estimate of US$0.19.

There was a rosy spot, as revenue climbed 6.5% to US$89.3mln, which whizzed past the consensus estimate of US$88.4mln.

But in late afternoon trade, shares in Del Frisco were down 8.3% to US$15.55.

Barteca deal tough to chew on

Its second announcement is the acquisition of Barteca, a two-decade-old Spanish Restaurant Group that owns Barcelona, an upmarket tapas restaurant, and Bartaco, a less formal South American street food establishment.

The takeover represents an attempt by Del Frisco’s to widen its repertoire beyond steakhouses and woo customers interested in different sorts of food.

But the price to acquire Barteca exceeds Del Frisco's market cap, which now hovers around US$300.1mln after today's decline.

The company’s board approved the takeover of Barteca, which is expected to be completed by second quarter’s close, subject to closing conditions.

Based in Irving, Texas, Del Frisco currently boasts more than 50 restaurants across 23 states and Washington D.C.

Quick facts: Del Frisco's Restaurant Group Inc

Price: - -

Market: NASDAQ
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Redx Pharma PLC's Lisa Anson updates on lead asset RXC004 and increased...

Redx Pharma PLC's (LON:REDX) Lisa Anson recaps on its lead product RXC004 which is in a Phase I clinical trial and is part of a potentially breakthrough group of cancer drugs called Porcupine inhibitors. Anson also details the recent investment by its majority shareholder Redmile which has...

1 hour, 10 minutes ago

2 min read